Cardiol Therapeutics (CRDL) Notes Payables (2021 - 2026)

Cardiol Therapeutics' Notes Payables history runs 6 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Notes Payables changed N/A year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
• Notes Payables was $2.7 million for Q1 2026 at Cardiol Therapeutics, up from $1.5 million in the prior quarter.
• Across five years, Notes Payables topped out at $3.6 million in Q1 2022 and bottomed at $2673.4 in Q3 2024.
• A 5-year average of $1.3 million and a median of $991230.6 in 2024 frame the typical range for Notes Payables.
• Peak annual rise in Notes Payables reached 493.8% in 2024, while the deepest fall reached 99.56% in 2024.
• Cardiol Therapeutics' Notes Payables stood at $309342.3 in 2022, then sank by 43.44% to $174948.7 in 2023, then slumped by 98.47% to $2673.4 in 2024, then surged by 57243.04% to $1.5 million in 2025, then surged by 74.44% to $2.7 million in 2026.
• Business Quant data shows CRDL's Notes Payables at $2.7 million in Q1 2026, $1.5 million in Q4 2025, and $2673.4 in Q3 2024.